Adalimumab
23CH134
Approved small_molecule active
Quick answer
Adalimumab for Crohn's Disease is a Approved program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Crohn's Disease
- Phase
- Approved
- Modality
- small_molecule
- Status
- active